18Fluoro-O-(2) Fluoroethyl-L-tyrosine (FET) PET For Localization Of Pituitary Adenomas In Patients With Cushing Disease
Mayo Clinic
Summary
The purpose of this research is to evaluate the performance \[sensitivity, specificity, accuracy\] of FET PET/CT imaging to detect ACTH-secreting pituitary adenoma, using operative findings and histopathology as truth standard.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: Patients must meet ALL criteria listed below for entry: * Biochemically diagnosed ACTH-dependent Cushing disease. * No previous pituitary surgery. * Planned to undergo pituitary surgery for localization/resection of adenoma. * No contraindications for PET/CT. * Recent (within 3 months) pituitary MR, or pending pituitary MR to be performed as close as possible to FET PET/CT. * Age ≥ 18 years. * Ability to provide informed consent. Exclusion Criteria: * Pregnant as determined by a pregnancy test as per institutional guidelines for individuals of child-bearing potential *…
Interventions
- DrugFluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET
Patients will receive intravenous administration of radiolabeled FET (5mCi ±10%) administered 20 minutes (±10minutes) prior to the initiation of the attenuation correction CT followed by the PET acquisition encompassing the participant's head/neck, centered on the pituitary gland.
Location
- Mayo Clinic in RochesterRochester, Minnesota